|
|
|
|
|
|
Sponsored by: |
Millennium Pharmaceuticals |
Information provided by: | Millennium Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00063791 |
The purpose of this study is to give patients who have had 4 or more prior lines of therapy for multiple myeloma access to VELCADE. The study is for patients who are not eligible for other clinical trials with VELCADE and for who VELCADE would otherwise not be available.
Condition | Intervention | Phase |
Multiple Myeloma |
Drug: Bortezomib |
Phase II |
Genetics Home Reference related topics: | aceruloplasminemia hemophilia |
MedlinePlus related topics: | Multiple Myeloma |
ChemIDplus related topics: | Dexamethasone Dexamethasone acetate Dexamethasone Sodium Phosphate Doxiproct plus Bortezomib |
Study Type: | Expanded Access |
Official Title: | An Open-Labeled, Randomized Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE in Patients With Relapsed Multiple Myeloma Who Have Failed Four or More Lines of Therapy |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Major Criteria:
Minor criteria:
Other Eligibility Requirements:
Exclusion Criteria:
United States, Alabama | |||||
Michael Meshad, Oncology Center | |||||
Mobile, Alabama, United States, 36608 | |||||
United States, Michigan | |||||
Henry Ford Health System | |||||
Detroit, Michigan, United States, 48202 | |||||
United States, Ohio | |||||
Toledo Clinic | |||||
Toledo, Ohio, United States, 43623 |
Millennium Pharmaceuticals |
Study ID Numbers: | M34102-052 |
First Received: | July 7, 2003 |
Last Updated: | February 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00063791 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|